English
Regional settings| Spread | 0.1324 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 0.001 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.2538 |
| Open | 2.2638 |
| 1-Year Change | 462.16% |
| Day's Range | 2.2138 - 2.2738 |
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.
BRIEF: For the nine months ended 30 September 2021, Finch Therapeutics Group Inc revenues increased from $5.9M to $17.7M. Net loss increased 49% to $39.1M. Revenues reflect Collaboration revenue increase from $5.6M to $17.7M. Higher net loss reflects Research and development - Balancing val increase of 69% to $41.3M (expense), General and administrative - Balancing increase of 93% to $14.6M (expense).
